Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

NCT04741997 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage III
Melanoma Stage IV
BRAF V600 Mutation

Interventions

DRUG: Encorafenib Pill
DRUG: Binimetinib Pill
DRUG: Nivolumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]